{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for tyrosine in Related Substance Name (approximate match)
Status:
Investigational
Source:
NCT03821233: Phase 1 Interventional Completed HER2-expressing Cancers
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04699630: Phase 2 Interventional Active, not recruiting Metastatic Breast Cancer
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03650348: Phase 1 Interventional Completed HER2-positive Breast Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03255070: Phase 1 Interventional Completed Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04501939: Phase 2 Interventional Active, not recruiting Chronic Lymphocytic Leukemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03541369: Phase 1 Interventional Terminated Relapsed/Refractory Acute Myeloid Leukemia (AML)
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02665065: Phase 3 Interventional Active, not recruiting Acute Myeloid Leukemia
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02988817: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab envedotin [INN]
Source URL:
Class:
PROTEIN
